MRI-based treatment of rectal cancer: Is prognostication of the recurrence risk solid enough to render radiation redundant?

Annals of Surgical Oncology

Volumn 21, Issue 1, 2014, Pages 197-204

  Sautter Bihl, Marie Luise ^a   Hohenberger, Werner ^b   Fietkau, Rainer ^b   Roedel, Claus ^c   Schmidberger, Heinz ^d   Sauer, Rolf ^b  

^a STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; HUMAN; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PREOPERATIVE RADIOTHERAPY; RECTUM CANCER; RECURRENCE RISK;

HUMANS; MAGNETIC RESONANCE IMAGING; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECTAL NEOPLASMS;

EID: 84891739790     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3236-7     Document Type: Article

References (64)

1. Heald R, Ryall R. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;327:1479-82.
2. Bernstein T, Endreseth B, Romundstad P, Wibe A. Improved local control of rectal cancer reduces distant metastases. Colorectal Dis. 2012;14:e668-78.
3. Bouchard P, Efron J. Management of recurrent rectal cancer. Ann Surg Oncol. 2010;17:1343-56.
4. Fleming FJ, Påhlman L, Monson JR. Neoadjuvant therapy in rectal cancer. Dis Colon Rectum. 2011;54:901-12.
5. Di Valentin T, Alam Y, Alsharm AA, Arif S, Aubin F, Biagi J, et al. Eastern Canadian colorectal cancer consensus conference: application of new modalities of staging and treatment of gastrointestinal cancers. Curr Oncol. 2012;19:169-74.
6. Schmiegel W, Pox C, Reinacher-Schick A, Adler G, Arnold D, Fleig W, et al. S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol. 2010;48:65-136.
7. IKNL-Integraal-Kankercentrum-Nederland. Dutch Guidelines Rectal Cancer. 2011. Available at www.oncoline.nl.
8. NCCN. Practice guideline in diagnosis and treatment of rectal cancer. National Cancer Comprehensive Network. 2013. Available at www.nccn.org.
9. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23:2479-516.
10. NICE. NICE clinical guideline 131. The diagnosis and management of colorectal cancer. 2011. Available at http://guidance.nice.org.uk/cg131.
11. van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575-82.
12. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811-20.
13. Mercury-Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333:779.
14. Al-Sukhni E, Milot L, Fruitman M, Beyene J, Victor JC, Schmocker S, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2012;19:2212-23.
15. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26:303-12.
16. Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol. 2008;47:20-31.
17. Birbeck KF, Macklin CP, Tiffin NJ, Parsons W, Dixon MF, Mapstone NP, et al. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg. 2002;235:449-57.
18. Glynne-Jones R, Mawdsley S, Pearce T, Buyse M. Alternative clinical end points in rectal cancer - are we getting closer? Ann Oncol. 2006;17:1239-48.
19. Dent OF, Chapuis PH, Haboubi N, Bokey L. Magnetic resonance imaging cannot predict histological tumour involvement of a circumferential surgical margin in rectal cancer. Colorectal Dis. 2011;13:974-81.
20. Taylor FG, Quirke P, Heald RJ, Moran B, Blomqvist L, Swift I, et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg. 2011;253:711-9.
21. Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011;29:3753-60.
22. Maurer CA, Mattiello D, Duwe J, Ruppert R, Ptok H, Strassburg J, et al. Oncological short-term effects and adverse events of MRI-guided selective neoadjuvant radiochemotherapy for rectal cancer. Anticancer Res. 2012;32:1721-8.
23. Strassburg J, Ruppert R, Ptok H, Maurer C, Junginger T, Merkel S, et al. MRI-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study. Ann Surg Oncol. 2011;18:2790-9.
24. Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet. 2009;373:821-8.
25. Bernstein T, Endreseth B, Romundstad P, on behalf of the Norwegian Colorectal Cancer Registry. What is a safe distal resection margin in rectal cancer patients treated by low anterior resection without preoperative radiotherapy. Colorectal Dis. 2012;14:48-55.
26. Eriksen MT, Arne Wibe M, Jon Haffner M, Wiig JN. Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy. Dis Colon Rectum. 2007;50:156-67.
27. Suit HD, Westgate SJ. Impact of improved local control on survival. Int J Radiat Oncol Biol Phys. 1986;12:453-8.
28. Hellman S. Stopping metastases at their source. New Engl J Med. 1997;337:996.
29. Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol. 2002;20:3199-205.
30. Glimelius B. Multidisciplinary treatment of patients with rectal cancer: development during the past decades and plans for the future. Ups J Med Sci. 2012;117:225-36.
31. Guillem JG, Díaz-González JA, Minsky BD, Valentini V, Jeong SY, Rodriguez-Bigas MA, et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol. 2008;26:368-73.
32. Colombo PE, Patani N, Bibeau F, Assenat E, Bertrand MM, Senesse P, et al. Clinical impact of lymph node status in rectal cancer. Surg Oncol. 2011;20:e227-33.
33. Kosinski L, Habr-Gama A, Ludwig K, Perez R. Shifting concepts in rectal cancer management. CA Cancer J Clin. 2012;62:173-202.
34. Hermanek P, Merkel S, Fietkau R, Rödel C, Hohenberger W. Regional lymph node metastasis and locoregional recurrence of rectal carcinoma in the era of TNM surgery. Implications for treatment decisions. Int J Colorect Dis. 2010;25:359-68.
35. Mercury Study Group, Shihab OC, Taylor F, Bees N, Blake H, Jeyadevan N, et al. Relevance of magnetic resonance imaging-detected pelvic sidewall lymph node involvement in rectal cancer. Br J Surg. 2011;98:1798-804.
36. Hermanek P, Hohenberger W, Fietkau R, Rödel C. Individualized magnetic resonance imaging-based neoadjuvant chemoradiation for middle and lower rectal carcinoma. Colorectal Dis. 2011;13:39-47.
37. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926-33.
38. Wolff HA, Hennies S, Herrmann MK, Rave-Fränk M, Eickelmann D, Virsik P, et al. Comparison of the micronucleus and chromosome aberration techniques for the documentation of cytogenetic damage in radiochemotherapy-treated patients with rectal cancer. Strahlenther Onkol. 2011;187:52-8.
39. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215-23.
40. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. New Engl J Med. 2004;351:1731-40.
41. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30:3827-33.
42. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. New Engl J Med. 2006;355:1114-23.
43. Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients - a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199-206.
44. Stephens RJ, Thompson LC, Quirke P, Steele R, Grieve R, Couture J, et al. Impact of short-course preoperative radiotherapy for rectal cancer on patients' quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol. 2010;28:4233-9.
45. Marijnen CA, van de Velde CJ, Putter H, van den Brink M, Maas CP, Martijn H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2005;23:1847-58.
46. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Late adverse effects of radiation therapy for rectal cancer - a systematic overview. Acta Oncol. 2007;46:504-16.
47. Nijkamp J, Kusters M, Beets-Tan RG, Martijn H, Beets GL, van de Velde CJ, et al. Three-dimensional analysis of recurrence patterns in rectal cancer: the cranial border in hypofractionated preoperative radiotherapy can be lowered. Int J Radiat Oncol Biol Phys. 2011;80:103-10.
48. Jabbour SK, Patel S, Herman JM, Wild A, Nagda SN, Altoos T, et al. Intensity-modulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits. Int J Surg Oncol. 2012;2012:891067.
49. Gwynne S, Mukherjee S, Webster R, Spezi E, Staffurth J, Coles B, et al. Imaging for target volume delineation in rectal cancer radiotherapy - a systematic review. Clin Oncol (R Coll Radiol). 2012;24:52-63.
50. Blomqvist L, Glimelius B. The 'good', the 'bad', and the 'ugly' rectal cancers. Acta Oncol. 2008;47:5-8.
51. Smith NJ, Barbachano Y, Norman AR, Swift RI, Abulafi AM, Brown G. Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg. 2008;95:229-36.
52. Rodel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13:679-87.
53. Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012;30:1620-7.
54. Rodel C, Arnold D, Becker H, Fietkau R, Ghadimi M, Graeven U, et al. Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer: is it time for a randomized phase III trial? Strahlenther Onkol. 2010;186:658-64.
55. Weiss C, Arnold D, Dellas K, Liersch T, Hipp M, Fietkau R, et al. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: a pooled analysis of three prospective phase I-II trials. Int J Radiat Oncol Biol Phys. 2010;78:472-8.
56. Dvorak J, Sitorova V, Ryska A, Sirak I, Richter I, Hatlova J, et al. Prognostic significance of changes of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma. Strahlenther Onkol. 2012;188:833-8.
57. Ofner D, Devries AF, Schaberl-Moser R, Greil R, Rabl H, Tschmelitsch J, et al. Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT(3)NxM0, low rectal cancer: a phase II study. Strahlenther Onkol. 2011;187:100-7.
58. Fietkau R. Rectal cancer: quo vadis, neoadjuvant and adjuvant (chemo) radiotherapy? Int J Colorectal Dis. 2010;25:285-7.
59. Rodel C, Sauer R, Fietkau R. The role of magnetic resonance imaging to select patients for preoperative treatment in rectal cancer. Strahlenther Onkol. 2009;185:488-92.
60. Ulrich A, Weitz J, Buchler MW. Rectal cancer. How much radiotherapy do surgery patients need? Chirurg. 2009;80:266-73.
61. Sautter-Bihl ML, Hohenberger W, Fietkau R, Rodel C, Schmidberger H, Sauer R. Rectal cancer: when is the local recurrence risk low enough to refrain from the aim to prevent it? Strahlenther Onkol. 2013;189:105-10.
62. Wibe A, Eriksen MT, Syse A, Myrvold HE, Soreide O. Total mesorectal excision for rectal cancer - what can be achieved by a national audit? Colorectal Dis. 2003;5:471-7.
63. Hohenberger W, Merkel S, Hermanek P. Volume and outcome in rectal cancer surgery: the importance of quality management. Int J Colorectal Dis. 2013;28:197-206.
64. Nagtegaal ID, van de Velde CJ, van der Worp E, Kapiteijn E, Quirke P, van Krieken JH. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol. 2002;20:1729-34.